Published on 21/12/2025
Understanding Investigator and Sponsor Roles in Causality Assessment
Introduction: Why Causality Roles Must Be Defined
Causality assessment is central to determining whether an adverse event (AE) is related to an investigational product (IP) in a clinical trial. Both investigators and sponsors play crucial roles in this process, but their responsibilities are distinct. Regulators such as the FDA, EMA, MHRA, and ICH guidance clearly outline the expectations for each stakeholder. Misalignment or poor documentation between investigator and sponsor causality assessments is one of the most common findings in regulatory inspections.
Investigators are closest to the patient and have first-hand clinical knowledge, while sponsors provide centralized oversight, pharmacovigilance expertise, and access to aggregate safety data. Both perspectives are necessary to ensure an accurate and comprehensive causality judgment. This article explores the responsibilities of investigators and sponsors, regulatory requirements, common challenges, and best practices for aligning causality assessments in clinical trials.
Investigator’s Role in Causality Assessment
The investigator is the primary medical professional responsible for patient care during the trial. Their role in causality assessment includes:
- First-hand evaluation: Reviewing the clinical presentation of the AE, including timing, lab results, and medical history.
- Initial judgment: Recording causality in the eCRF, typically
For example, if a patient in an oncology trial develops neutropenia, the investigator must decide whether the condition is likely caused by the investigational chemotherapy agent or by underlying disease. Their judgment forms the first step of causality assessment.
Sponsor’s Role in Causality Assessment
While investigators provide the frontline assessment, sponsors are responsible for ensuring the accuracy and consistency of causality across the trial. Sponsor responsibilities include:
- Aggregate analysis: Reviewing AEs across all patients and sites to identify safety patterns.
- Medical review: Pharmacovigilance physicians re-assess causality using broader datasets, literature, and drug mechanism knowledge.
- Regulatory submissions: Ensuring that causality is consistent in SAE narratives, SUSAR reports, and databases such as EudraVigilance.
- Oversight: Ensuring that investigator assessments are complete, logical, and aligned with protocol and safety profiles.
For instance, if multiple sites report “hepatotoxicity” as unrelated, but the sponsor sees a safety signal across pooled data, the sponsor may classify these events as “possibly related” in regulatory submissions.
Reconciling Investigator and Sponsor Assessments
Discrepancies between investigator and sponsor causality assessments are common. Regulators expect sponsors to reconcile differences transparently. Best practices include:
- Maintaining both assessments in the safety database with clear attribution.
- Explaining differences in SUSAR reports or DSURs.
- Documenting the rationale for sponsor reclassification, supported by aggregate evidence.
For example, during a Phase III cardiovascular trial, investigators recorded myocardial infarction as “not related.” However, sponsor analysis across multiple cases suggested a potential safety signal, leading the sponsor to report the event as “possibly related” in regulatory filings.
Regulatory Expectations for Defined Roles
Authorities emphasize clear delineation of roles in causality assessment:
- FDA: Requires investigator causality assessments in IND safety reports, while allowing sponsors to provide independent judgment.
- EMA: Mandates inclusion of both investigator and sponsor causality in EudraVigilance submissions for SUSARs.
- MHRA: Inspections often highlight insufficient documentation of differences between assessments.
- ICH E2A: Reinforces the need for both local (investigator) and global (sponsor) perspectives in causality attribution.
During inspections, regulators often request side-by-side listings of investigator vs sponsor causality judgments, verifying whether discrepancies are justified and explained.
Challenges in Managing Roles
Several challenges complicate the division of roles in causality assessment:
- Subjectivity: Investigators may underreport causality due to bias toward investigational products.
- Data gaps: Sponsors may lack real-time clinical context when making aggregate judgments.
- Communication barriers: Sponsors and sites may not align on causality definitions or expectations.
- Inspection risk: Regulators may issue findings if discrepancies are not adequately reconciled.
These challenges highlight the need for SOPs, training, and clear documentation practices.
Best Practices for Harmonizing Investigator and Sponsor Roles
To ensure alignment and compliance, best practices include:
- Train investigators on standardized causality assessment tools such as WHO-UMC or Naranjo.
- Require written rationale for all causality classifications in eCRFs.
- Establish reconciliation workflows for sponsor vs investigator differences.
- Document causality rationale in SAE narratives and regulatory submissions.
- Conduct regular safety review meetings involving investigators and sponsor safety teams.
For example, in a global oncology trial, sponsors implemented joint causality review calls with investigators, reducing discrepancies and inspection findings.
Key Takeaways
Causality assessment requires active participation from both investigators and sponsors. Investigators provide patient-level clinical insights, while sponsors contribute aggregate data and regulatory oversight. Successful management of causality roles involves:
- Clear definition of responsibilities.
- Transparent reconciliation of differences.
- Documentation of rationale for all causality judgments.
- Training and communication to ensure consistency across the trial.
By following these practices, sponsors and investigators can align on causality assessments, meet regulatory expectations, and ensure accurate safety reporting.